Daily ReportSep 21, 2026
Sepsis, September 21 edition
We read 21 papers and selected 3.
Summary
The strongest evidence today comes from an updated meta-analysis of 10,308 children, which found that balanced crystalloids reduce hyperchloremia and renal replacement therapy but do not improve mortality. Two large-scale computational studies provide complementary advances: an interpretable machine-learning model for mortality prediction in sepsis-induced coagulopathy and a biologically informed temporal graph model for early prediction of multi-organ dysfunction.
Research Themes
- Fluid resuscitation and clinically meaningful negative evidence
- Interpretable machine learning for sepsis risk stratification
- Biologically informed artificial intelligence for multi-organ dysfunction prediction
Selected Articles
1. Balanced crystalloids versus 0.9% saline for fluid resuscitation in children with septic shock: an updated systematic review and meta-analysis of randomized controlled trials.
This PRISMA 2020 systematic review and meta-analysis included six randomized trials involving 10,308 children with sepsis or septic shock. Balanced crystalloids did not reduce mortality or acute kidney injury, but they reduced hyperchloremia, hypernatremia, and the need for renal replacement therapy, while increasing hyperlactatemia slightly.
Impact: The study provides the largest summarized pediatric evidence base in the supplied papers and importantly excludes a clinically meaningful mortality benefit, preventing overinterpretation of physiologic advantages. It supports balanced crystalloids as a reasonable default when available while emphasizing that fluid selection should not delay antibiotics or hemodynamic support.
Clinical Implications: Balanced crystalloids can be considered an equally safe or physiologically preferable first-line fluid for pediatric septic shock, particularly when avoiding chloride loading is desirable. Clinicians should not expect mortality reduction and should prioritize early recognition, antimicrobials, source control, and individualized hemodynamic management.
Key Findings
- Six randomized trials including 10,308 children were analyzed.
- Balanced crystalloids did not reduce in-hospital or ICU mortality compared with 0.9% saline: 3.7% versus 3.9%, RR 0.95, 95% CI 0.75-1.21.
- Balanced crystalloids reduced renal replacement therapy, hyperchloremia, and hypernatremia, but did not reduce acute kidney injury or length of stay.
Methodological Strengths
- PRISMA 2020-guided systematic review with searches across four major databases.
- Random-effects meta-analysis with prespecified registration in PROSPERO and quantitative assessment of mortality, renal, electrolyte, and safety outcomes.
Limitations
- Only six trials were available, and differences in fluid protocols, populations, and clinical settings may contribute to heterogeneity.
- The evidence does not establish superiority for specific balanced solutions or for all pediatric septic shock subgroups.
Future Directions: Future trials should use standardized pediatric sepsis definitions, fluid dosing strategies, and kidney-related outcomes, while examining whether specific subgroups with renal or metabolic vulnerability benefit more from balanced crystalloids.
BACKGROUND: 0.9% (normal) saline remains the most widely used bolus resuscitation fluid in paediatric septic shock, despite a supraphysiological chloride content that may impair renal perfusion and cause hyperchloraemic acidosis. Whether balanced crystalloids, which more closely approximate plasma, improve clinical outcomes in children remains uncertain. METHODS: Following PRISMA 2020 guidelines, PubMed/MEDLINE, Scopus, ScienceDirect and Web of Science were searched upto July 2026 for randomized trials of balanced or buffered crystalloids versus 0.9% saline in children (< 18 years) with sepsis or septic shock.
2. Development and Validation of an Interpretable Machine Learning Model to Predict Mortality in Patients With Sepsis-Induced Coagulopathy: Multicenter Cohort Study.
This retrospective multicenter cohort study used 12,030 patients with sepsis-induced coagulopathy from MIMIC-IV, eICU-CRD, and a Chinese hospital to develop and externally validate mortality prediction models. The XGBoost model achieved AUCs of 0.899 internally and 0.882 and 0.904 externally, outperforming traditional scores; SHAP analysis highlighted anion gap, red blood cell distribution width, lactate, bilirubin, and age.
Impact: The study combines large, heterogeneous clinical databases with external validation and interpretable predictions, addressing a major barrier to bedside adoption of machine learning. Its performance and online implementation suggest potential for individualized early risk stratification, although prospective impact on outcomes remains unproven.
Clinical Implications: The model may support early identification of high-risk patients with sepsis-induced coagulopathy and help prioritize monitoring or escalation of care. It should be used as decision support rather than a replacement for clinician judgment until prospective and impact-based validation is completed.
Key Findings
- The study included 12,030 patients: 7,980 from MIMIC-IV, 3,815 from eICU-CRD, and 235 from Tianjin Medical University General Hospital.
- XGBoost achieved AUCs of 0.899 in internal validation and 0.882 and 0.904 in two external validation cohorts.
- The model outperformed SOFA, APACHE II, SAPS II, and OASIS, with the leading SHAP features being anion gap, red blood cell distribution width, lactate, total bilirubin, and age.
Methodological Strengths
- Large multicenter data sources with two external validation cohorts.
- Comparison with four established clinical scores and use of calibration, decision-curve analysis, and SHAP-based interpretability.
Limitations
- The retrospective design is vulnerable to selection bias, measurement differences, and residual confounding.
- The model was not prospectively evaluated for effects on treatment decisions, workflow, or patient outcomes.
Future Directions: Prospective silent-mode and impact studies should assess calibration across health systems, subgroup fairness, alert burden, clinician response, and whether model-guided management improves mortality or other patient-centered outcomes.
BACKGROUND: Sepsis-induced coagulopathy (SIC) is a common and severe complication in patients with sepsis, characterized by microvascular thrombosis, systemic endothelial damage, and markedly increased short-term mortality. Existing traditional clinical risk scoring systems demonstrate limited accuracy and fail to capture complex, nonlinear physiological interactions, underscoring the urgent need for advanced prognostic tools. OBJECTIVE: The objective of this study was to develop and validate an interpretable machine learning (ML) model using large-scale, multicenter databases to predict early mortality in intensive care unit (ICU) patients with SIC and to evaluate its predictive performance and clinical utility compared with traditional clinical risk scores.
3. PathSepsisNet: a pathway-aware temporal graph attention network integrating inflammatory crosstalk dynamics for early prediction of multi-organ dysfunction in sepsis.
PathSepsisNet is a biologically informed temporal graph attention network trained on 29,765 adults with Sepsis-3 from MIMIC-IV using the first 12 ICU hours to predict multi-organ dysfunction 12-36 hours later. It achieved AUROC 0.895 and AUPRC 0.901, outperforming BiLSTM, Transformer, and logistic regression, while pathway divergence and node-importance analyses provided mechanistic interpretability.
Impact: This paper advances beyond purely statistical prediction by encoding inflammatory pathway crosstalk into the model architecture and introducing a pathway divergence score. Although the model lacks external validation and does not outperform the best black-box boosting methods in raw AUROC, it addresses the clinically important accuracy-interpretability gap.
Clinical Implications: A pathway-aware model could support earlier recognition of patients likely to develop multi-organ dysfunction and may help generate mechanistically informed monitoring or intervention hypotheses. Clinical deployment requires external validation, prospective calibration, and demonstration that pathway-based explanations improve clinician decisions.
Key Findings
- The model was trained on 29,765 adults with Sepsis-3 using only the first 12 hours of ICU data and strict leakage prevention.
- PathSepsisNet achieved AUROC 0.895 and AUPRC 0.901, exceeding BiLSTM, Transformer, and logistic regression, while XGBoost and LightGBM had marginally higher raw AUROC.
- The Pathway Divergence Score had AUROC 0.872; CytokineStorm, NLRP3/P2X7, and mitochondrial dysfunction were the most influential pathway modules.
Methodological Strengths
- The architecture explicitly integrates established biological pathway relationships with temporal clinical data.
- The study prevents use of SOFA sub-scores as inputs and provides pathway-level interpretability through attention, node importance, and the Pathway Divergence Score.
Limitations
- The model was developed and validated within MIMIC-IV without independent external validation.
- Pathway activation states were estimated from routine biomarkers and therefore may not directly represent molecular pathway activity; clinical benefit was not tested.
Future Directions: External validation across hospitals and populations should be combined with prospective biomarker studies to test whether inferred pathway states correspond to molecular measurements. Future impact trials should determine whether pathway-level explanations improve early treatment, monitoring, or outcomes.
Sepsis-induced multi-organ dysfunction syndrome (MODS) remains a leading cause of intensive care unit (ICU) mortality worldwide. The complex interplay among inflammatory signaling pathways TLR4/NF-κB, NLRP3/P2X7 and Nrf2/HO-1 plays a critical role in determining organ damage trajectories, yet existing artificial intelligence (AI) models fail to capture these molecular dynamics. We propose PathSepsisNet, a pathway-aware temporal graph attention network that integrates biological pathway crosstalk knowledge into a deep learning architecture for early MODS prediction. We developed a biologically-informed graph neural network in which six nodes represent molecular pathway activation states